(19)
(11) EP 2 062 571 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.12.2012 Bulletin 2012/51

(45) Mention of the grant of the patent:
14.11.2012 Bulletin 2012/46

(21) Application number: 08020342.5

(22) Date of filing: 21.11.2008
(51) International Patent Classification (IPC): 
A61K 9/107(2006.01)
A61K 47/10(2006.01)
A61K 47/44(2006.01)
 A61K 9/48(2006.01)
A61K 47/26(2006.01)

(54)

Self-emulsifying pharmaceutical composition with enhanced bioavailability

Selbstemulgierende pharmazeutische Zusammensetzung mit verbesserter Bioverfügbarkeit

Composition pharmaceutique à auto-émulsion avec une biodisponibilité améliorée

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 21.11.2007 US 944239

(43) Date of publication of application:
27.05.2009 Bulletin 2009/22

(73) Proprietor: INNOPHARMAX INC.
Taipei 11492 (TW)

(72) Inventors:
  • Hao, Wei-Hua
    Taipei 114, Taiwan, R.O.C. (TW)
  • Wang, Jong-Jing
    Taipei 114, Taiwan, R.O.C. (TW)
  • Hsu, Chang-Shan
    Taipei 114, Taiwan, Taiwan R.O.C. (TW)

(74) Representative: Becker Kurig Straus 
Bavariastrasse 7
80336 München
80336 München (DE)


(56) References cited: : 
EP-A- 0 274 870
WO-A-98/33512
FR-A- 2 775 596
 EP-A- 0 985 412
WO-A-98/40094
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).